Short answer
Intellia Therapeutics, Inc. (NTLA) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $68M (+16.9% year over year) and net income of −$413M.
- Top risk flagged: Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
FY2025 key financial metrics · XBRL
- Revenue
- $68M
- +16.9% YoY
- Net income
- −$413M
- +20.5% YoY
- Operating margin
- -651.7%
- +271.4 pp YoY
- EPS (diluted)
- −$3.81
- +27.4% YoY
- ROE
- -61.5%
- −1.9 pp YoY
- Operating cash flow
- −$395M
- −13.1% YoY
Source: XBRL data from the Intellia Therapeutics, Inc. (NTLA) FY2025 10-K on SEC EDGAR. USD.
Intellia Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: biotechnology firm developing CRISPR-based in vivo genome editing therapies targeting severe diseases
- New emphasis on Phase 3 products lonvo-z and nex-z for hereditary angioedema and transthyretin amyloidosis, with commercial launch preparation for lonvo-z in H1 2027
- Strategic focus shifted towards advancing first-in-class systemic CRISPR therapies with single IV infusions in outpatient settings
- Employee count increased with shares issued to 116.3M from 102.0M year-over-year, net loss reduced to $412.7M from $519.0M in 2024
- Collaboration revenue grew to $67.7M from $57.9M, signaling stronger partner-based funding streams in 2025
Management Discussion & Analysis
- No capital allocation information such as buybacks, dividends, or capex mentioned
- Forward-looking statements referenced but no specific management outlook or guidance included
Risk Factors
- Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
- Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility
- Operational risk: $195.1M committed lease payments starting mid-2026 for new Cambridge office/lab space could pressure cash flow
- Competitive risk: reliance on Regeneron collaboration contributing $23.7M in cost reimbursements subject to partnership risks
- Financial risk: $394.7M net cash used in operating activities in 2025, with runway into H2 2027 excluding milestones or new capital raises
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.